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Abstract Current concepts conceive ‘‘breast cancer’’ as a
complex disease that comprises several very different types
of neoplasms. Nonetheless, breast cancer treatment has
considerably improved through early diagnosis, adjuvant
chemotherapy, and endocrine treatments. The limited
prognostic power of classical classiﬁers determines con-
siderable over-treatment of women who either do not
beneﬁt from, or do not at all need, chemotherapy. Several
gene expression based molecular classiﬁers (signatures)
have been developed for a more reliable prognostication.
Gene expression proﬁling identiﬁes profound differences in
breast cancers, most probably as a consequence of different
cellular origin and different driving mutations and can
therefore distinguish the intrinsic propensity to metastasize.
Existing signatures have been shown to be useful for
treatment decisions, although they have been developed
using relatively small sample numbers. Major improve-
ments are expected from the use of large datasets, subtype
speciﬁc signatures and from the re-introduction of func-
tional information. We show that molecular signatures
encounter clear limitations given by the intrinsic probabi-
listic nature of breast cancer metastasis. Already today,
signatures are, however, useful for clinical decisions in
speciﬁc cases, in particular if the personal inclination of the
patient towards different treatment strategies is taken into
account.
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Introduction
Gene expression of a tumor is a complex intermediate
phenotype that is determined by many different factors: (1)
the host genotype, (2) eventual somatic mutations and
genomic alterations, (3) the cell from which the tumor
originated,and(4)thespeciﬁcmicroenvironmentintermsof
stromacells,inﬁltratingcellsandcellsignalingmolecules.It
is reasonable to assume that any difference between two
tumors in their patho-physiological state should be repre-
sented by some difference in gene expression. This is true
despite the fact that while genes and the messenger RNAs
derived from them are not the executers of biological
function,theycannonethelessbeusedasmarkersofit.Even
events thatare completely independentofgene transcription
such as protein modiﬁcations, as a part of the cellular pro-
gram,elicitatranscriptionalresponsethatcanbedetectedby
expression proﬁling.
However, tumors are heterogeneous and the different
cell populations contained in different areas of the same
tumor might well differ for their potential to progress and
metastasize. The multistep carcinogenesis model predicts
that tumors evolve through the consecutive acquisition of
genetic and epigenetic alterations towards a more and more
aggressive phenotype inasmuch as they acquire the char-
acteristics needed for progression [proliferation, resistance
to apoptosis, scattering, migration and invasion, stimula-
tion of vessel growth, survival in the blood stream (anti-
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vival and growth in the target tissue] through random
mutation and epigenetic changes followed by selection of
the cells that carry a growth advantage in the speciﬁc
environment [1–5]. One of the predictions of the multistep
carcinogenesis model is that the ‘‘metastatic phenotype’’
might be a characteristic of only a very small subpopula-
tion of the cells within the primary tumor and that the
metastasizing cells could acquire additional mutations that
are not present in the primary tumor [2, 6]. These features
would escape from detection by expression proﬁling (or
any other genomic technique such as comparative genome
hybridization on arrays) unless one analyzes each poten-
tially unique cell population within a tumor, an impossible
enterprise. Another recent theory predicts that metastasis
arises from cancer ‘‘stem cells’’, better deﬁned as ‘‘cancer
initiating cells’’ that might stay latent in the primary tumor
and escape to metastasis when local conditions, for
instance in hypoxia, induce their scattering. In retrospect,
the success of metastasis prediction by expression proﬁling
of the primary tumor was not so obvious and it is still not
very clear how this can be reconciled with the multistep
carcinogenesis model [7–10].
The current view of carcinogenesis considers the tumor
cells themselves as main actors in carcinogenesis. Muta-
tions of oncogenes and tumor suppressor genes initiate and
promote the development of the tumor, hence these
mutations determine its fate. From this point of view, the
analysis of the actual tumor cells instead of the whole
tumor that also contains many host ﬁbroblasts, endothelial
cells, and blood cells, would be expected to yield the best
information on the molecular status of the tumor. The
presence of host cells was expected to dilute the signal
derived from the mutated tumor cell population [11].
However, the importance of the tumor stroma and of
its interactions with the neoplastic cells are increasingly
recognized as important, if not determining, factors in the
evolution of a tumor [12–17]. This is also supported by
evidence that gene expression proﬁling of the entire tumor
yields reliable signatures. We have recently shown that
many of the genes contained in the metastasis signature
developed by comparing many tumors of different tissues
and metastases of unmatched tumors [18] are expressed
by stromal ﬁbroblast or endothelial cells. Genes encoding
proteins of the extracellular space, which are produced at
least in part by stromal cells, can be used to construct a
prognostic signature [19]. Stroma cells, long believed to
be passive by-standers, can undergo mutations that drive
them to contribute to tumor progression: p53 mutations,
for instance, have been detected in stromal ﬁbroblasts in
40% of the tumors analyzed, prevalent even in the
absence of p53 mutations in the tumor epithelial cells,
and these mutations predicted lymphnode metastasis [20].
For the purpose of prognosis, it appears therefore useful
or even necessary to screen all the tumor compartments
for potential markers and not only the tumor cell itself.
For breast cancer, prognostic signatures are expected to
reduce the tendency to apply what has been seen as over-
treatment. Following the existing guidelines, adjuvant
chemotherapy is offered to most breast cancer patients.
Many of these patients have tumors that have a low risk of
developing metastases or that do not respond to existing
chemotherapies. A more precise prognosis of the risk of
relapse and a response prediction are needed.
Technical issues
Microarray technology has developed to considerable
maturity. State of the art platforms and protocols guar-
antee high reproducibility and a low intrinsic variability.
It has been shown that most of the variability in micro-
array experiments derives from the biological sample
itself, even when conducted under apparently identical
conditions. The second most important source of vari-
ability is introduced by the operator whereas the intrinsic
oscillation of present microarrays is negligible [21]. Also,
in our experience, the correlation between gene expres-
sion data generated by microarray and those obtained by
more classical approaches such as real time PCR is
excellent. Most differences can eventually be attributed to
differences in the region of selection of probes and
primers (U. Pfeffer, unpublished observation) since
alternative splicing appears to be more the rule than the
exception. The same applies for cross-platform variation
of microarray data [22]. The latest addition to the tech-
nological battery are arrays that contain several probes for
each single exon of each single gene of the human gen-
ome and are expected to yield additional information on
alternative splicing and variant expression as well as more
robust data [23]. So far, no large breast cancer studies
using these arrays have published.
The sensitivity of microarrays has grown continuously
and the amount of tissue needed to perform the analysis has
been greatly reduced. Latest generation microarray analy-
ses start with 100 ng total RNA that can be isolated from
very small amounts of tissue. Analysis of material obtained
from ﬁne needle biopsies is therefore possible, potentially
allowing for pre-operative diagnostic approaches [24–26].
However, the smaller the sample, the higher the risk for
sampling non-representative areas of a typically heteroge-
neous tumor. The ratio between tumor epithelial cells and
stroma cells sampled also varies in ﬁne needle aspirates.
For this reason, whenever possible, larger pieces that have
accurately been selected by the pathologist should be used.
Sample conservation remains critical for the success of
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123expression proﬁling applications. Yet the laborious and
logistically demanding procedure of liquid nitrogen freez-
ing of intra-operative samples can be substituted by
conservation in RNA inhibiting pre-ﬁxation solution such
as RNAlater [27] or HOPE [28] that also facilitate long-
term storage thereby reducing the costs and eventually
increasing stability of biological molecules. Data on the
involvement of microRNAs in breast cancer are growing
and therefore sample conservation and RNA extraction
should also consider the need to isolate small RNAs, since
not all miRNA screening procedures accept total RNA as a
starting material.
A major concern has been the virtually absent overlap of
signatures produced using different platforms. Unfortu-
nately, not a single study to date has hybridized a large
number of samples to two different platforms. It is there-
fore difﬁcult to conclude to which degree the different
platforms actually reveal the same gene expression events.
The lack of overlap can probably be attributed mainly to
different patient populations analyzed, which greatly
determines the genes selected for the signatures, as dis-
cussed below.
Breast cancer subtypes
Microarray gene expression proﬁling reliably yields the
complex intermediate phenotype of gene expression of a
sample. The gene expression phenotype of a tumor
reﬂects its past history in terms of cell origin, its present
in terms of exposure to oxygen and nutrients, growth
factors and hormones, inﬂammation and tumor inﬁltrate
which in turn are believed to determine its future potential
to develop metastases. The ﬁrst indication of the power of
gene expression proﬁling with microarray came from the
analysis of tumors sampled before and after chemotherapy
and, in two cases, of matched lymphnode metastases [29].
This work showed the existence of molecularly deﬁned
subgroups. Gene expression patterns in two tumors from
the same individual were almost always more similar to
each other than to any other sample. Additional studies
have conﬁrmed that primary tumors and their metastases
share similar expression proﬁles [30, 31] although several
genes that are differently expressed have been identiﬁed
[32, 33].
Sorlie et al. [34] showed that breast cancer cases fall into
two large molecular classes that correspond almost per-
fectly to the status of estrogen receptor expression as
analyzed by ligand binding assays or immunohistochem-
istry. A bioinformatic analysis of the two classes revealed
that they correspond to profoundly different tumors. Even
after the stepwise removal of several hundreds of the genes
that best discriminate between the two classes, almost all
cases were still correctly assigned to the estrogen receptor
a positive or negative classes of tumors [35]. The differ-
ence between these two classes is consistent with the
hypothesis that the two different tumor types derive from
different progenitor cells. For this reason, the two classes
are also deﬁned as luminal and basal type. However, gene
expression proﬁling reveals additional subtypes that are
reproducibly formed after hierarchical clustering of breast
cancer datasets containing more than hundred cases (hence
containing a sufﬁcient number of cases for each subtype
class) [34, 36]. The estrogen receptor a positive type is
subdivided into luminal A, luminal B and eventually C
clusters and the estrogen receptor a negative type contains
the basal-like, her2-like, and a ‘‘normal like’’ cluster. A
similar classiﬁcation has independently been obtained by
Sotiriou et al. [36]. A more recent elaboration of breast
cancer microarray expression proﬁles has conﬁrmed the
subtypes identiﬁed before [37]. The main determinant of
subtypes remain HER2 and estrogen receptor status [38,
39]. The analysis by Hu et al. [37] tentatively names one of
the estrogen receptor a negative subtypes ‘‘IFN-like’’ since
STAT1 and several interferon induced genes are among the
master discriminators of this cluster. Analyses of this type
point to the identiﬁcation of genes or pathways whose
differential expression characterizes single clusters. This is
particularly evident for the HER2 subtype. Tumors that
cluster in this subtype show over-expression of HER2/neu/
ERBB2, the EGF receptor family member whose ampliﬁ-
cations determine responsiveness to the humanized
antibody trastuzumab, which is directed against the HER2
encoded protein [40, 41]. Similarly, more deﬁned subcl-
usters have been identiﬁed as being formed by tumors
harboring BRCA1 and BRCA2 mutations, and a closely
related subcluster shows alterations downstream of the two
hereditary breast cancer genes without having the genes
themselves mutated [42, 43]. It is most likely that, step by
step, information on the molecular nature of the tumors
clustering together will be obtained for most of the subcl-
usters. Intriguingly, not all tumors belonging to a
subcluster must necessarily express the master discrimi-
nator gene(s) nor is expression of these genes sufﬁcient for
assigning a single case to a speciﬁc subcluster. In fact,
HER2 expressing tumors are found among nearly all the
subtypes [34]. This indicates that tumors of any subtype
can over-express HER2 without loosing their identity, but
in this case, HER2 over-expression most probably has only
a minor role in the etiology of the speciﬁc tumor and hence
a lower potential as a response marker.
Molecular subtypes have a clinical relevance inasmuch
as they have different propensities to metastasize. The
genes that characterize the different subtypes form the
intrinsic subtype signature that can prognosticate clinical
behavior [34, 36, 37, 44]. Its development as a real time
PCR based test has been reported [45].
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negative breast cancers most probably are derived from
different tumor progenitor cells. Weinberg et al. [46] have
recently shown that the cell of origin is a major determinant
of the propensity to metastasize. It cannot be excluded, at
present, that the molecular subtypes identiﬁed correspond to
different progenitor cells downstream to ERa? (luminal) or
ERa- (basal) progenitor cells. More likely, subtypes cor-
respond to tumors sharing the same driving mutation or at
leastthesameaffectedpathway,asitisevidentfortheHER2
and BRCA1 and 2 cases. Further studies on molecular
characteristics will eventually identify pathway mutations
and lead to a more profound understanding of etiological
events in breast cancer carcinogenesis.
Signatures
The identiﬁcation of molecular subtypes with clinical rel-
evance indicated that it should be possible to develop
prognostic signatures with an elevated accuracy in classi-
fying tumors into risk groups that deserve differential
treatment or eventually no treatment at all. This endeavor
has been undertaken by several groups. The general
approach is a retrospective analysis of deep frozen breast
cancer specimens with known follow-up, selection of dis-
criminator genes by a variety of bioinformatics and
statistical methods, and the construction of a predictive
multigene classiﬁer on the base of the follow-up informa-
tion available. The statistical aspects of this approach have
been the argument of a survey of these kinds of studies
where many ﬂaws in the experimental design were
revealed [47]. Essentially, two datasets are needed: one to
develop the classiﬁer (training set) and another to test the
classiﬁer (test or validation set). These two sets can be
obtained by a random split if the original dataset is large
enough. In this case, a validation on a third, completely
independent set is desirable. In alternative, signatures can
be developed by the cross-validation method where single
cases are left out from the training set in an iterative
manner. The cases left out are then classiﬁed in order to
validate the method.
A major problem with existing sample collections is that
most of the women with breast cancer have received
adjuvant chemotherapy. Therefore, a tumor that later
developed a metastasis is of certain metastatic potential,
whereas a tumor that did not metastazie could be a tumor
without metastatic potential, a tumor that has not yet
yielded a metastasis but will eventually do so, or a
potentially metastatic tumor that has responded to adjuvant
chemotherapy. A further complication is that breast cancers
can give metastases even numerous years after removal of
the primary tumor. This is best taken into account by
working with cases with a very long follow-up. The
metastasis-free cases that represent response to chemo-
therapy are most probably limited to a relatively small
group of cases. However, these cases will participate in
determining the signature. In the theoretical case of a
cohort entirely composed of tumors with metastatic
potential but with half of these being responsive to che-
motherapy, these latter would be classiﬁed as ‘‘low risk’’.
This aspect could be dealt with by using cases that have not
received adjuvant chemotherapy. However, with current
standards of care such cases are rare and are becoming
progressively rarer.
A variety of signatures have been developed and have
been recently exhaustively reviewed [48–55]. Two of these
signatures have already been developed for commerciali-
zation as centralized laboratory tests and are presently
being tested in large prospective trials. The Oncotype DX
 
recurrence score has been developed as real time PCR
assay that can be performed on formalin ﬁxed parafﬁn
embedded (FFPE) tissues [56]. The selection of genes that
form the classiﬁer was based on three preliminary studies
using real time PCR on FFPE samples. The most robust
and informative genes were incorporated into a 16 gene
classiﬁer and analyzed in comparison to ﬁve housekeeping
genes. The test is directed towards estrogen receptor a
positive lymphnode negative cancers and yields a contin-
uous prognostic score and predicts beneﬁt from tamoxifen
(in the low and intermediate risk group) and from adjuvant
chemotherapy (in the high risk group). The test has
recently been included in the recommendations of the
American Society of Clinical Oncology. A prospective trial
(Trial Assigning Individualized Options for Treatment—
TAILORx) with a planned accrual of at least 10,000
patients intends to answer the question of whether inter-
mediate risk patients beneﬁt from chemotherapy [57]. The
genes tested mainly monitor ER and HER2 status and
proliferation.
Laura van’t Veer et al. [58, 59] from the Netherlands
Cancer Institute in Amsterdam developed a 70-gene clas-
siﬁer (commercialized as MammaPrint
 ) based on two-
color microarray technology (initially using Rosetta
Inpharmatics inkjet microarray technology and subse-
quently Agilent’s microarray platform). The signature was
built using the cross validation leave-one-out procedure on
78 informative lymph node negative cases and was sub-
sequently validated on a partially overlapping cohort of
295 lymph node negative and positive cases. The classiﬁer
assigns cases to poor and good prognosis groups. The
comparison of the 70 gene classiﬁer with the NIH and St.
Gallen criteria shows that the genomic approach clearly
outperforms both. One study claimed, however, that this
classiﬁer works comparably to the Nottingham Prognostic
Index (NPI) [60]. An additional validation study revealed a
more than 90% chance of being free of disease after
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1235 years for patients classiﬁed in the low risk group. This
signature is being prospectively validated in the Microarray
in Node-Negative Disease May Avoid Chemotherapy
(MINDACT) trial where the enrollment of 6,000 patients is
planned [61]. Patients discordantly scored by the classical
Adjuvant! Online (www.adjuvantonline.com) and the
genomic MammaPrint
  assay will be randomized to
receive or not receive chemotherapy. This trial will yield
microarray data from a very large cohort that will also
contain many cases that, according to the genomic classi-
ﬁer, did not receive chemotherapy. The use of these data
will certainly allow major improvements of existing
molecular signatures.
Other genomic prognostic classiﬁers such as the 76-gene
classiﬁer (Rotterdam signature) [62], the wound healing
signature [63] and the invasive gene signature [64] have
been developed. In a more straightforward approach the
group of Sotiriou and colleagues has given the long sought
answer to the question whether grade 2 cancers are an
independent entity or whether they incorporate features of
grade 1 and 3 cancers. A 97-gene (128 probe sets) dis-
criminator was built on Affymetrix HU133A arrays using
cancers of pathological grade 1 and 3. This discriminator
was then applied to grade 2 cancers that showed either a
grade 1 or 3 proﬁle rather than an intermediate expression
phenotype [65]. These signatures are also being developed
towards commercialization [66].
The overlap of genes contained in these signatures is
very low. However, the main determinants of all the sig-
natures are proliferation, ER-status, HER2-status and, less
prominently, angiogenesis, invasiveness and apoptosis.
Most probably these signatures detect the same biological
processes and pathways involved in metastasis. Depending
on the actual patient cohort, the assay platform and the
analytic algorithms used, different genes are selected for
the signature. This is also supported by a bioinformatics
analysis that shows the possibility to select other equally
informative 70 gene classiﬁer sets from the data set used by
Van’t Veer and Bernards [67]. This most probably indi-
cates that many genes, probably several hundred or even
more than one thousand, are actually related to disease free
survival, and that the genes selected for any one classiﬁer
heavily depend on the patient cohort. In an additional
study, the same authors calculated that for the development
of a stable, cohort-independent classiﬁer, several thousands
of patients are needed [68].
A validation of several signatures (intrinsic subtype, 70-
gene classiﬁer, wound healing signature, recurrence score
and two gene classiﬁer) revealed that with the exception of
the latter, all signatures have a similar discriminating
power showing 77 to 80% agreement in outcome scoring.
Importantly, the combination of the signatures did not
perform better, again indicating that the different
signatures actually identify the same molecular character-
istics by using different marker genes [44].
This, however, also means that a considerable part of
cases is misclassiﬁed by any and all of the signatures. This
raises the question of whether the existing signatures can
be improved to yield a more reliable prediction of outcome.
This is of particular importance if one keeps in mind that
the classiﬁer is to be used to withhold patients from che-
motherapy. In this context, misclassiﬁcation means not to
treat a woman who might have beneﬁted from chemo-
therapy. This is also important since this aspect determines
the major skepticism among the oncologists who must
decide whether or not to base the treatment decision they
offer to the patients on molecular signatures.
Limits of molecular signatures
In order to explore the possibility of compiling the ulti-
mate signature we have performed a simple simulation
based on a publicly available breast cancer dataset (Gene
Expression Omnibus, GEO1456) of 159 consecutive
breast cancer cases from Stockholm with follow-up
information of at least 8 years [69]. Forty of the 159 cases
developed distant metastases. We have clustered these 159
cases using several gene lists that were obtained by
selecting genes contained in speciﬁc Gene Ontology cat-
egories [70] that were associated with the parameter
‘‘relapse’’ with a P value below 0.001. The Gene Ontol-
ogy terms ‘‘cell cell signaling’’, ‘‘cell death’’, ‘‘cell
growth’’, ‘‘cell proliferation’’, ‘‘kinase’’, ‘‘metabolism’’,
‘‘signal transduction’’, ‘‘transcription regulator activity’’
were selected since they stand for different functional
aspects that are involved in the process of metastasis. We
then used the genes selected from each category sepa-
rately for hierarchical clustering of the samples. This
procedure necessarily produces highly discriminating gene
lists since the classiﬁer is developed on the same dataset
to which it is applied. For the development of a molecular
signature, these classiﬁers must be tested on an indepen-
dent test or validation set. Here we ask instead, how well
the classiﬁers developed can distinguish between cases
with and without relapse in the optimal situation. In all
cases, two main clusters are formed, one is enriched in
cases with metastases and the other contains only very few
of the metastatic cancer samples (Fig. 1). The bar under
each clustergram indicates the follow-up information for
each case (pink = relapse, brown = no relapse). As
expected, the classiﬁers thus work on the dataset on which
they have been developed and all eight gene lists yield a
similar discrimination. Yet for each classiﬁer, several
cases with relapse cluster together with most of the cases
without relapse. This could be simply due to a limitation
of the single classiﬁer with each misclassifying a different
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123Fig. 1 Raw data from 159
consecutive breast cancer cases
were obtained from Gene
Expression Omnibus
(GSE1954). Data were
preprocessed by the GCRMA
algorithm implemented in
Bioconductor. Genes that were
signiﬁcantly associated with the
parameter ‘‘relapse’’
(P\0.001) were selected
among the genes listed in the
Gene Ontology categories
indicated. Hierarchical cluster
analysis (Pearson correlation,
average linkage) was performed
using the genes selected. Cases
with relapse are indicated in
pink, cases without relapse in
brown in the bar beneath each
clustergram. The eight
annotation categories yield a
distinction in two major
clusters. Most of the cases with
metastases cluster together
whereas the other cluster
contains only few metastatic
cases (the yellow bar indicates
the separation between the two
major clusters)
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123subset of cases. This would be the case if, for instance, a
group of metastatic cancers are similar to the non-meta-
static samples as far as proliferation is concerned but not
when metabolism is considered. However, when we
looked at the samples actually misclassiﬁed by the dif-
ferent classiﬁer gene lists we noticed that several cases
were misclassiﬁed by many or even by all of the eight
classiﬁers (Table 1). Three of forty cases with metastases
clustered together with the more benign samples for all of
the eight lists and ﬁve cases were misclassiﬁed by seven
out of eight lists. We also tested combinations of the lists
using either all of the genes contained in the eight lists
(combined lists), only those genes of the eight lists that
are associated with relapse with a P\10
-6 or using the
ﬁve most strongly associated genes of each list. Again, a
similar picture is obtained (Fig. 2): two clusters with a
clearly different content of metastatic cases are obtained
and the ‘‘good prognosis’’ cluster contains six misclassi-
ﬁed cases, among which the ﬁve samples that are most
frequently misclassiﬁed by the single lists. Misclassiﬁ-
cation could have been expected more easily for cases that
showed metastases at very long times after diagnosis, but
this is not the case (Table 1).
We then compiled a list of genes that are signiﬁcantly
differently expressed between correctly classiﬁed cases
with metastases and the ﬁve most frequently misclassi-
ﬁed cases using a permutation test (Signiﬁcance Analysis
of Microarrays [71]). The genes selected are expressed at
similar levels in misclassiﬁed cases and in cases without
metastases. When we tried to identify genes that are
Table 1 Misclassiﬁcation of breast cancer cases by Gene Ontology based functional clustering
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86 86 86 86 86 86 86 7 86 86 5.53
155 155 155 155 155 155 155 7 155 155 155 1.04
72 72 2 3.82
125 125 2 125 3.99
210 210 2 0.76
219 219 2 0.90
105 1 6.65
184 1 5.95
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227 1 0.67
148 5.63
160 4.30
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# misclassified  7 8 7 6 6 5 5 7 5 6 7
% misclassified  17.5 20 17.5 15 15 12.5 12.5 17.5 12.5 15 17.5
The sample numbers are indicated for cases that were misclassiﬁed by the Gene Ontology based gene lists or by combined lists. The gray scale
indicates the frequency of misclassiﬁcations (dark gray = 8 of 8, mid gray = 7 of 8, light gray = 2 of 8). The disease free survival is indicated
for each case on the right most column. Note that 3 cases are misclassiﬁed by clustering with any list and 5 cases are misclassiﬁed by 7 of 8 gene
lists. Combined list do not perform better. There is no obvious relation between misclassiﬁcation and time of disease free survival
Fig. 2 Hierarchical clustering of 159 breast cancer samples using a
gene list containing genes selected from the combination of all eight
gene lists used in Fig. 1 containing 1,085 genes. Genes that are
associated with the parameter ‘‘relapse’’ with P value below 10
-6
were selected. The combination of all gene lists equally misclassiﬁes
a number of cases, among which those misclassiﬁed by all the single
gene lists
Clin Exp Metastasis (2009) 26:547–558 553
123expressed at signiﬁcantly different levels in misclassiﬁed
cases with metastases and cases without metastasis no
gene passed the threshold. The misclassiﬁed cases are
evidently very similar to tumors that do not metastasize,
hence molecular classiﬁers fail to classify them correctly.
The problem of misclassiﬁcation
Intrinsic misclassiﬁcation could come about through var-
ious reasons: (1) annotation errors (erroneously annotated
metastases), (2) metastases derived from different clini-
cally non overt primary breast cancers (second primaries),
(3) acquisition of the metastatic phenotype by only a very
small subpopulation of cells in the primary tumor which
would not leave a trace on the expression proﬁle, (4)
metastasis of non-metastatic cancers. Although annotation
errors can never be totally excluded we believe that they
would not occur in as many as 15% of the cases. Simi-
larly, while non overt second primaries cannot be
completely excluded they are expected to account for less
than the proportion detected. Acquisition of the metastatic
phenotype by only a small subpopulation of the primary
tumor cells, or even after the cells have left the primary
tumor, is exactly what the multistep carcinogenesis model
predicts. The fact that gene expression proﬁling of the
bulk of the primary tumor allows to prognosticate
metastasis is a violation of the multistep carcinogenesis
theory as Bernards and Weinberg [8] pointed out. These
authors proposed that the fate of the tumor is determined
right from the initiating event, the transforming mutation,
and it might also depend on the cell of origin [46]. These
two features, cellular origin and driving mutations, are
what microarray proﬁling is best at detecting. Hence most
if not all of the prognostic power of the approach might
reside in the correct and exhaustive identiﬁcation of these
two crucial aspects of tumor biology. Yet this does not
exclude that, at least in some case, the metastatic phe-
notype is acquired by an additional mutation by a single
cell in the primary tumor or by a cell that, although
devoid of metastatic growth characteristics, acquires this
potential through mutations. A potential scenario could
involve an invasive, anoikis resistant and extravasation
competent cell that is able to survive but not to proliferate
in a target tissue until a mutation in a receptor gene
confers growth factor independent growth. Such a muta-
tion would be rare, since it must occur in the limited
number of cells that have formed micrometastases, thus as
a consequence the primary tumor would be classiﬁed as a
‘‘non metastatic’’ one.
The multistep carcinogenesis model therefore meets a
model of probabilistic metastasis that predicts that any
invasive cancer can yield metastases but it does so with
varying probabilities (being in no case equal to zero). This
probability relies on the cell of origin and the driving
mutation as well as on the genetic background of the host
and the tumor microenvironment, including the host’s
immune response, inﬂammation and tumor inﬁltrate [19].
The acquisition of additional mutations that confer an
increased metastatic propensity accounts for the residual
metastasis risk that is not derived from the above features
and cannot not be predicted. Microarray expression pro-
ﬁling measures, to different extents, all of the above risk
modulating factors, with cellular origin and driving
mutation probably being the master discriminators that
correspond to the main clusters formed by unsupervised
hierarchical clustering. Differences in the tumor micro-
environment, inﬂammation, host factors and the like, if
they have an inﬂuence on the tumor, will leave a trace in
the expression proﬁle. The mutation in a subpopulation or,
worse, in an already disseminated cell, escapes expression
proﬁling and therefore yields a subfraction of tumors that
are ‘‘misclassiﬁed’’. This suggests that a relatively acute
multistep carcinogenesis model occurs in a set percentage
of cases, in the cohort used here approximately 10%, that
are likely responsible for metastasis from a primary tumor
with a ‘‘non-metastatic’’ phenotype. This would also
suggest that the same misclassiﬁcation would be made by
more traditional grading approaches, as the cells with true
metastatic potential are quite rare within the primary
tumor, thus the histopathological grade would also miss-
classiﬂy these same tumors.
Improvement of molecular signatures
This interpretation postulates a theoretical limit to any
prognostic procedure that relies on the primary tumor. With
a relatively high degree of accurate relapse prognostica-
tion, present signatures might already be close to this
theoretical limit. But how can we drive them further to
actually reach the limit?
In our opinion, three approaches will permit to improve
the existing signatures:
• Large sets of samples on which to build and test
signatures
• Subtype speciﬁc signatures
• Re-introduction of functional information into the
signatures
The need for large datasets has been highlighted by the
analyses of Ein-Dor and colleagues: in very large datasets
the effect of the actual composition of the sample types
will be diluted and any possible tumor type will actually be
present. Hence, the signatures are expected to become
more robust and more generally applicable [67, 68].
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improved prognostic power since tumors of different sub-
types are profoundly different and therefore most likely
follow different routes to metastasis. Such signatures
become possible if very large datasets are analyzed.
The re-introduction of functional information is
expected to yield more robust signatures inasmuch as the
genes contained in the signature are mechanistically
linked to the process of metastasis. The matrix metallo-
proteinase 1 (MMP1), for example, has been shown to be
functionally linked to metastasis and is contained in the
general metastasis signature developed by Ramaswamy
et al. [18] and in the metastasis signature obtained from
highly metastatic MDA-MB231 mammary breast cancer
cells [72]. MMP1 expression shows a very clear expres-
sion difference in breast cancer samples [19]. If over-
expression of this proteinase could be shown to be nec-
essary for metastasis in a speciﬁc subtype of breast
cancers, it could become a particularly robust, causally
involved marker. The wound healing signature [63] and
the invasive gene signature [64] have exploited this
functionally oriented approach and were able to show that
it is possible to derive valuable prognostic signatures from
it. Figure 1 also illustrates that the simple use of func-
tional information already contained in Gene Ontology
allows for compiling molecular classiﬁers. Similarly,
Achyrya and colleagues used pathway information to
reﬁne the estimation of relapse-free survival and sensi-
tivity to chemotherapy [73]. In addition to an improved
prognostication, information on response to chemotherapy
can be obtained.
Most probably, a complex functionally deﬁned signature
would consist in a meta-signature that has been built by
taking into account several functional aspects of metastasis.
The use of annotations like Gene Ontology is, however, not
sufﬁcient for this approach because the functional infor-
mation for genes is still relatively limited and mainly
depends on the context in which the genes have been
analyzed. Experimental evidence of gene function should
therefore be collected in a context speciﬁc manner before
building signatures.
An additional improvement of signatures could be
expected from the application of latest generation micro-
array platforms with more exhaustive (exon rather than
transcript coverage) and more robust sets of gene speciﬁc
probes [23].
MicroRNAs
Concurrently, new actors in the cellular regulation plot are
being investigated. Small non coding RNAs, such as 21–
23-mer microRNAs that regulate mRNA stability and
translatability show important functions in tumor initiation
and progression [74, 75]. Apparently, their expression can
be taken as a surrogate of breast cancer subtypes [76]
although differences in miRNA expression within the sin-
gle subtypes cannot be excluded. Integration of miRNA
with mRNA expression proﬁles could eventually further
improve molecular signatures. New technologies reveal
many more transcripts than previously estimated [77],
hence new entries of transcripts or even transcript classes
with functional and/or prognostic signiﬁcance may soon be
detected.
Clinical application
Oncologists are debating over the need or the possibility
to integrate information obtained from genomic signa-
tures into the process of treatment decisions. This is
already useful in situations where a reasonable doubt on
the best treatment persists after classical prognostication,
as it could be the case for small, ER-positive, HER2-
negative, lymphnode negative, low proliferation index
(KI67) cases of grade 2 cancers. Since the application of
molecular signatures aims at reducing over-treatment,
thereby invariably increasing the risk of under-treatment
(in the case of misclassiﬁcation), much will depend on
the individual orientation of the patient. Molecular pro-
ﬁling can be offered as an additional source of
information if the patient would prefer to avoid chemo-
therapy, if possible.
Molecular proﬁling, as a relatively recent technology,
still has elevated costs, partly determined by the fact that
existing protocols are offered as centralized services. It can
be foreseen that with the growing introduction of genomic
approaches into the clinical routine, de-centralized devices
will become available and lead to cost reductions.
Genomics also has the potential to substitute several clas-
sical analyses since the correlation between gene
expression data and classical analytical methods for prog-
nostic breast cancer markers (estrogen and progesterone
receptor and KI67 expression) is excellent (U. Pfeffer,
unpublished observations). Hence, it is conceivable that
future pathologists will obtain most of their information on
a breast cancer sample from a single complex highly
standardized genomic assay.
It is important that the screening of breast cancer sam-
ples using whole genome platforms continues in order to
design better prognostic signatures. This should not be
compromised by the application of existing classiﬁers.
Data obtained from validation studies of molecular classi-
ﬁers (if publicly funded and published on peer reviewed
journals) must be made available to the scientiﬁc
community.
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